Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Jorge Cortes, ASH 2022: IDH1 inhibitors in the treatment of IDH1-mutant acute myeloid leukaemia – results from a phase II pivotal clinical trial

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jan 5th 2023

Professor Jorge Cortes (Georgia Cancer Center, GA, USA) discusses the results from a recent clinical trial that were presented at ASH 2022. Abstract 2757:  ‘Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial

Disclosures: Jorge Cortes is a consultant for Novartis, Pfizer, Takeda, Sun Pharma and Rigel. He has received grant/research support from Novartis and Sun Pharma, and is on the advisory board for Novartis.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the 64th ASH Annual Meeting & Exposition

Access more Leukaemia content here

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup